Q32 Bio (QTTB) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Q32 Bio (QTTB) has outperformed Turn Therapeutics (TTRX) over the past year, gaining 317.0% versus a gain of 147.6%. Q32 Bio is the larger company by market cap ($249.6 million vs $247.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | TTRX |
|---|---|---|
| Share price | $8.34 | $8.10 |
| Market cap | $249.57M | $247.49M |
| 1-day change | -1.65% | -6.31% |
| YTD return | +151.20% | +105.46% |
| 1-year return | +317.00% | +147.55% |
| 5-year return | -91.12% | — |
| P/E ratio (TTM) | 2.32 | — |
| EPS (TTM) | $3.60 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $53.74M | — |
| Net income (latest FY) | $29.82M | $-3.19M |
| Operating margin | 31.45% | — |
| Net margin | 55.49% | — |
| 52-week high | $23.57 | $16.45 |
| 52-week low | $1.98 | $2.70 |
| Distance from 52-week high | -64.62% | -50.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +375.66% | +208.83% |
| Average volume | 692.58K | 119.32K |
| Shares outstanding | 29.92M | 30.57M |
| Employees | 25 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed TTRX by 169.4 percentage points over the past year.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
QTTB vs TTRX FAQ
Which is bigger, Q32 Bio or Turn Therapeutics?
Q32 Bio (QTTB) is larger, with a market capitalization of $249.57M compared with $247.49M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, QTTB or TTRX?
QTTB returned +317.00% over the past 12 months, compared with +147.55% for TTRX (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.